- Home
- KGS vs MLTX Comparison
KGS vs MLTX Comparison
Compare KGS & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGS
- MLTX
- Stock Information
- Founded
- KGS 2011
- MLTX 2021
- Country
- KGS United States
- MLTX Switzerland
- Employees
- KGS N/A
- MLTX N/A
- Industry
- KGS
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- KGS
- MLTX Health Care
- Exchange
- KGS Nasdaq
- MLTX Nasdaq
- Market Cap
- KGS 3.0B
- MLTX 2.8B
- IPO Year
- KGS 2023
- MLTX N/A
- Fundamental
- Price
- KGS $32.53
- MLTX $47.92
- Analyst Decision
- KGS Strong Buy
- MLTX Strong Buy
- Analyst Count
- KGS 10
- MLTX 7
- Target Price
- KGS $41.20
- MLTX $73.33
- AVG Volume (30 Days)
- KGS 1.1M
- MLTX 427.3K
- Earning Date
- KGS 08-11-2025
- MLTX 08-06-2025
- Dividend Yield
- KGS 5.55%
- MLTX N/A
- EPS Growth
- KGS N/A
- MLTX N/A
- EPS
- KGS 0.54
- MLTX N/A
- Revenue
- KGS $1,273,461,000.00
- MLTX N/A
- Revenue This Year
- KGS $17.66
- MLTX $103.42
- Revenue Next Year
- KGS $6.52
- MLTX N/A
- P/E Ratio
- KGS $60.29
- MLTX N/A
- Revenue Growth
- KGS 45.41
- MLTX N/A
- 52 Week Low
- KGS $24.84
- MLTX $31.42
- 52 Week High
- KGS $50.43
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- KGS 36.90
- MLTX 59.90
- Support Level
- KGS $33.17
- MLTX $46.37
- Resistance Level
- KGS $34.35
- MLTX $49.29
- Average True Range (ATR)
- KGS 0.91
- MLTX 1.61
- MACD
- KGS -0.16
- MLTX -0.02
- Stochastic Oscillator
- KGS 10.66
- MLTX 78.46
About KGS Kodiak Gas Services Inc.
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to primarily fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.